IRLAB Therapeutics AB (publ) (FRA:6IRA)
Germany · Delayed Price · Currency is EUR 0.1812
+0.0016 (0.89%)
At close: Jan 9, 2026
IRLAB Therapeutics AB Income Statement
Financials in millions SEK. Fiscal year is January - December.
Millions SEK. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2015 - 2019 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2015 - 2019 |
Operating Revenue | 85.56 | 94.63 | 5.68 | 61.14 | 207.78 | - | Upgrade |
Other Revenue | -0 | - | - | - | - | 0.3 | Upgrade |
| 85.56 | 94.63 | 5.68 | 61.14 | 207.78 | 0.3 | Upgrade | |
Revenue Growth (YoY) | 69.03% | 1566.57% | -90.71% | -70.58% | 69160.67% | -19.36% | Upgrade |
Cost of Revenue | 116.19 | 136.29 | 128.41 | 125.91 | 81.74 | 65.63 | Upgrade |
Gross Profit | -30.63 | -41.66 | -122.73 | -64.77 | 126.05 | -65.33 | Upgrade |
Selling, General & Admin | 45.71 | 46.18 | 53.08 | 42.48 | 31.02 | 23.97 | Upgrade |
Other Operating Expenses | -8.35 | -19.46 | -0.04 | -0.03 | 38.97 | 0.01 | Upgrade |
Operating Expenses | 41.76 | 31.31 | 57.36 | 47.23 | 73.47 | 26.23 | Upgrade |
Operating Income | -72.4 | -72.97 | -180.09 | -112 | 52.58 | -91.56 | Upgrade |
Interest Expense | -18.9 | -10.48 | -0.2 | -0.3 | -0.37 | -0.2 | Upgrade |
Interest & Investment Income | 1.52 | 2.46 | 3.13 | - | 0 | 0 | Upgrade |
Currency Exchange Gain (Loss) | -2.14 | -2.14 | -0.68 | -1.11 | -0.43 | 0.1 | Upgrade |
Other Non Operating Income (Expenses) | -0 | - | 0 | - | - | -0 | Upgrade |
EBT Excluding Unusual Items | -91.91 | -83.13 | -177.84 | -113.41 | 51.78 | -91.65 | Upgrade |
Pretax Income | -91.91 | -83.13 | -177.84 | -113.41 | 51.78 | -91.65 | Upgrade |
Earnings From Continuing Operations | -91.91 | -83.13 | -177.84 | -113.41 | 51.78 | -91.65 | Upgrade |
Net Income | -91.91 | -83.13 | -177.84 | -113.41 | 51.78 | -91.65 | Upgrade |
Net Income to Common | -91.91 | -83.13 | -177.84 | -113.41 | 51.78 | -91.65 | Upgrade |
Shares Outstanding (Basic) | 59 | 52 | 52 | 52 | 52 | 48 | Upgrade |
Shares Outstanding (Diluted) | 59 | 52 | 52 | 52 | 52 | 48 | Upgrade |
Shares Change (YoY) | 13.14% | - | 0.07% | 0.16% | 8.54% | 17.45% | Upgrade |
EPS (Basic) | -1.57 | -1.60 | -3.43 | -2.19 | 1.00 | -1.92 | Upgrade |
EPS (Diluted) | -1.57 | -1.60 | -3.43 | -2.19 | 1.00 | -1.92 | Upgrade |
Free Cash Flow | -53.64 | -65.79 | -165.14 | -145.49 | 127.93 | -89.61 | Upgrade |
Free Cash Flow Per Share | -0.91 | -1.27 | -3.18 | -2.81 | 2.47 | -1.88 | Upgrade |
Gross Margin | -35.80% | -44.03% | - | -105.94% | 60.66% | - | Upgrade |
Operating Margin | -84.61% | -77.11% | -3171.72% | -183.20% | 25.30% | -30520.67% | Upgrade |
Profit Margin | -107.43% | -87.85% | -3132.07% | -185.50% | 24.92% | -30551.00% | Upgrade |
Free Cash Flow Margin | -62.70% | -69.52% | -2908.47% | -237.97% | 61.57% | -29869.33% | Upgrade |
EBITDA | -71.69 | -72.08 | -179.17 | -111.27 | 53.07 | -91.23 | Upgrade |
EBITDA Margin | -83.78% | -76.17% | - | -182.00% | 25.54% | - | Upgrade |
D&A For EBITDA | 0.71 | 0.89 | 0.92 | 0.74 | 0.49 | 0.33 | Upgrade |
EBIT | -72.4 | -72.97 | -180.09 | -112 | 52.58 | -91.56 | Upgrade |
EBIT Margin | -84.61% | -77.11% | - | -183.20% | 25.30% | - | Upgrade |
Revenue as Reported | 97.66 | 114.08 | 5.72 | 61.28 | 207.91 | 0.4 | Upgrade |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.